You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-negative Breast Cancer

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-negative Breast Cancer, Advanced Breast Cancer Trial in Guangzhou (Organoid-guided treatment, Taxane, Capecitabine)

Not yet recruiting
  • HER2-negative Breast Cancer
  • Advanced Breast Cancer
  • Organoid-guided treatment
  • +5 more
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Oct 22, 2023

Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

Not yet recruiting
  • Breast Cancer
  • Ovarian Function Suppression + Aromatase Inhibitor
  • Adjuvant Chemotherapy + Ovarian Function Suppression
  • (no location specified)
May 19, 2023

Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer Trial (Ribociclib, Fulvestrant,

Not yet recruiting
  • Locoregional Recurrence
  • +2 more
  • (no location specified)
Jul 18, 2022

Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine Trial in Changsha (UTD1 combined with capecitabine)

Recruiting
  • Metastatic HER2 Negative Breast Carcinoma
  • +3 more
  • UTD1 combined with capecitabine
  • Changsha, China
    Quchang Ouyang
Sep 9, 2022

Advanced ER+, HER2-Negative Breast Cancer Trial in Waltham (Elacestrant)

Completed
  • Advanced ER+, HER2-Negative Breast Cancer
  • Waltham, Massachusetts
    Radius Pharmaceuticals, Inc.
Aug 16, 2022

Breast Cancer Trial (Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC)

Not yet recruiting
  • Breast Cancer
  • Utidelone Injection in combination with AC
  • Docetaxel Injection in combination with AC
  • (no location specified)
Jan 10, 2023

Breast Cancer Trial in Bani Suwayf, Fayoum (Atorvastatin 80mg, )

Recruiting
  • Breast Cancer
  • Atorvastatin 80mg
  • placebo
  • BanÄ« Suwayf, Egypt
  • +1 more
Oct 31, 2022

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023

    Breast Cancer Trial in Boston, Pittsburgh, Dallas (Nivolumab, Ipilimumab)

    Active, not recruiting
    Has Results
    • Breast Cancer
    • Boston, Massachusetts
    • +2 more
    Oct 21, 2022

    Breast Cancer Stage II Trial in Xi'an (Anlotinib)

    Recruiting
    • Breast Cancer Stage II
    • Xi'an, Shannxi Province, China
      Xijing Hospital Affiliated to Air Force Military Medical Univers
    Sep 25, 2022

    Breast Cancer Trial in Guangzhou (Tucidinostat, Capecitabine, Endocrine Therapy)

    Recruiting
    • Breast Cancer
    • Guangzhou, Gangdong, China
      Shusen Wang
    Nov 1, 2022

    Triple Negative Breast Cancer, HER2-negative Breast Cancer Trial in Tampa (HER2 - primed Dendritic cells, HER3 - primed

    Recruiting
    • Triple Negative Breast Cancer
    • HER2-negative Breast Cancer
    • HER2 - primed Dendritic cells
    • HER3 - primed Dendritic cells
    • Tampa, Florida
      Moffitt Cancer Center
    Jan 10, 2023

    Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer Trial in Madison (18F-DCFPyL)

    Recruiting
    • Breast Cancer
    • +2 more
    • Madison, Wisconsin
      University of Wisconsin School of Medicine and Public Health
    Oct 18, 2022

    Breast Cancer Trial in Birmingham (Letrozole, Everolimus, TRC105)

    Active, not recruiting
    • Breast Cancer
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Dec 13, 2022

    HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab

    Recruiting
    • HER2-positive Breast Cancer
    • +17 more
    • ALX148
    • Fam-Trastuzumab Deruxtecan-Nxki
    • Chicago, Illinois
    • +1 more
    May 19, 2023

    Breast Tumor Female, Breast Cancer, Breast Carcinoma Trial in Portland (Nivolumab, Ipilimumab, Bicalutamide)

    Recruiting
    • Breast Neoplasm Female
    • +3 more
    • New York, New York
    • +1 more
    Dec 21, 2022

    Breast Cancer Trial in Canada (CFI-402257, Paclitaxel)

    Active, not recruiting
    • Breast Cancer
    • Vancouver, British Columbia, Canada
    • +3 more
    Jan 30, 2023

    CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective

    Recruiting
    • Breast Cancer
    • +2 more
      • Erlangen, Germany
        Department of Gynecology and Obstetrics, Erlangen University Hos
      May 12, 2023

      HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma Trial in Houston (L-NMMA)

      Recruiting
      • HER2-negative Breast Cancer
      • +3 more
      • Houston, Texas
        Houston Methodist Neal Cancer Center
      Jan 12, 2023

      HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

      Recruiting
      • HER2-negative Breast Cancer
      • +5 more
      • Camrelizumab with vinorelbine and cisplatin
      • Beijing, Beijing, China
        Peking University First Hospital
      Oct 15, 2022

      Breast Cancer Trial in Canton (TTI-101, Palbociclib, Aromatase inhibitor (AI))

      Recruiting
      • Breast Cancer
      • Saint Louis, Missouri
      • +2 more
      Jan 12, 2023

      HER2-negative Breast Cancer, Advanced Solid Tumor Trial in Singapore (ADG106, Doxorubicin, Cyclophosphamide)

      Recruiting
      • HER2-negative Breast Cancer
      • Advanced Solid Tumor
      • Singapore, Singapore
        National University Hospital
      Jun 9, 2022

      Solid Tumor Trial (Dalpiciclib)

      Not yet recruiting
      • Solid Tumor
      • (no location specified)
      Aug 22, 2022

      Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using

      Recruiting
      • HER2 Negative Breast Cancer
      • Response monitoring (no intervention)
      • Albuquerque, New Mexico
        University of New Mexico Comprehensive Cancer Center
      Apr 21, 2022

      HER2-negative Breast Cancer Trial (Gemcitabine combined with eribulin)

      Not yet recruiting
      • HER2-negative Breast Cancer
      • Gemcitabine combined with eribulin
      • (no location specified)
      Mar 2, 2022